Eos Med Chem, Stock List, pls kindly check:
EOS Med Chem, Medicinal Chemical is Big is China TOP 100 CRO comapny, mainly in Med-chemicals, Custom synthesis. We have GMP, ISO plant plant serving you.
搜索此博客
2017年10月26日星期四
2017年10月25日星期三
NMR, HPLC98.97%, LCMS, (2R,6R)-2,6-Dimethylmorpholine, CAS NO.:171753-74-5, 1KG in stock.
NMR, HPLC, LCMS, COA, Pls kindly check:
Name: (2R,6R)-2,6-Dimethylmorpholine
CAS NO.: 171753-74-5
Molecular Formula: C6H13NO
Molecular Weight: 115.17
Molecular Structure:
Name: (2R,6R)-2,6-Dimethylmorpholine
CAS NO.: 171753-74-5
Molecular Formula: C6H13NO
Molecular Weight: 115.17
Molecular Structure:
2017 China CPHI: E1M35
EOS Med Chem, Medchem is Big
執大象,天下往,往而無害,安平泰
労働時間: Beijing Time 4:00AM~11:00PM
郵箱: info@eosmedchem.com ; eosmedchem@gmail.com
辦公室: 0086-531-69905422-806(直通)
攜帶番號 & WhatsApp & Wechat: +8618653174435
住所: Diaozhen Chemical Industrial Park, Jinan City, China
Skype: willgutian
QQ: 2393923585 NMR, HPLC 98.7%, LCMS, Product name: SOLITHROMYCIN, CAS:760981-83-7, 100G in stock
NMR, HPLC, LCMS,COA, Pls kindly check:
Name: Solithromycin
CAS NO.: 760981-83-7
Chemical Formula: C43H65FN6O10
Exact Mass: 844.47462
Molecular Weight: 845.01
Elemental Analysis: C, 61.12; H, 7.75; F, 2.25; N, 9.95; O, 18.93
Appearance: Solid powder
Purity: >98%
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark
Solubility: Soluble in DMSO.
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C
REFERENCES
1: Jamieson BD, Ciric S, Fernandes P. Safety and Pharmacokinetics of Solithromycin in Subjects with Hepatic Impairment. Antimicrob Agents Chemother.
2: Vandevelde NM, Tulkens PM, Muccioli GG, Van Bambeke F. Modulation of the activity of moxifloxacin and solithromycin in an in vitro pharmacodynamic model of Streptococcus pneumoniae naive and induced biofilms. J Antimicrob Chemother. 2015 Feb 23. pii: dkv032.
3: Farrell DJ, Mendes RE, Jones RN. Antimicrobial Activity of Solithromycin against Serotyped Macrolide-Resistant Streptococcus pneumoniae Isolates Collected from U.S. Medical Centers in 2012. Antimicrob Agents Chemother. 2015 Apr;59(4):2432-4.
4: Keelan JA, Pugazhenthi K. Trans-placental passage and anti-inflammatory effects of solithromycin in the human placenta. Placenta. 2014 Dec;35(12):1043-8. doi: 10.1016/j.placenta.2014.09.009. Epub 2014 Sep 22.
5: Miura Y, Payne MS, Keelan JA, Noe A, Carter S, Watts R, Spiller OB, Jobe AH, Kallapur SG, Saito M, Stock SJ, Newnham JP, Kemp MW. Maternal intravenous treatment with either azithromycin or solithromycin clears Ureaplasma parvum from the amniotic fluid in an ovine model of intrauterine infection. Antimicrob Agents Chemother. 2014 Sep;
6: Jensen JS, Fernandes P, Unemo M. In vitro activity of the new fluoroketolide solithromycin (CEM-101) against macrolide-resistant and -susceptible Mycoplasma genitalium strains. Antimicrob Agents Chemother. 2014 Jun;58(6):3151-6. doi: 10.1128/AAC.02411-14. Epub 2014 Mar 17.
7: Piccinelli G, Fernandes P, Bonfanti C, Caccuri F, Caruso A, De Francesco MA. In vitro activity of solithromycin against erythromycin-resistant Streptococcus agalactiae. Antimicrob Agents Chemother. 2014;58(3):1693-8. doi: 10.1128/AAC.02210-13. Epub 2013 Dec 30. PubMed PMID: 24379197;
8: Mallegol J, Fernandes P, Melano RG, Guyard C. Antimicrobial activity of solithromycin against clinical isolates of Legionella pneumophila serogroup 1. Antimicrob Agents Chemother. 2014;58(2):909-15. doi:
9: Keelan JA, Kemp MW, Payne MS, Johnson D, Stock SJ, Saito M, Fernandes P, Newnham JP. Maternal administration of solithromycin, a new, potent, broad-spectrum fluoroketolide antibiotic, achieves fetal and intra-amniotic antimicrobial protection in a pregnant sheep model. Antimicrob Agents Chemother. 2014;58(1):447-54. doi: 10.1128/AAC.01743-13. Epub 2013 Nov 4.
10: Mallegol J, Fernandes P, Seah C, Guyard C, Melano RG. Determination of in vitro activity of solithromycin at different pHs and its intracellular activity tested against clinical isolates of Neisseria gonorrhoeae from a laboratory collection. Antimicrob Agents Chemother. 2013 Jun 24.
11: Kobayashi Y, Wada H, Rossios C, Takagi D, Charron C, Barnes PJ, Ito K. A novel macrolide/fluoroketolide, solithromycin (CEM-101), reverses corticosteroid insensitivity via phosphoinositide 3-kinase pathway inhibition. Br J Pharmacol. 2013 Jul;169(5):1024-34. doi: 10.1111/bph.12187.
Name: Solithromycin
CAS NO.: 760981-83-7
Chemical Formula: C43H65FN6O10
Exact Mass: 844.47462
Molecular Weight: 845.01
Elemental Analysis: C, 61.12; H, 7.75; F, 2.25; N, 9.95; O, 18.93
2017 China CPHI: E1M35
EOS Med Chem, Medchem is Big
執大象,天下往,往而無害,安平泰
労働時間: Beijing Time 4:00AM~11:00PM
郵箱: info@eosmedchem.com ; eosmedchem@gmail.com
辦公室: 0086-531-69905422-806(直通)
攜帶番號 & WhatsApp & Wechat: +8618653174435
住所: Diaozhen Chemical Industrial Park, Jinan City, China
Skype: willgutian
QQ: 2393923585
TECHNICAL DATA
Purity: >98%
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark
Solubility: Soluble in DMSO.
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C
REFERENCES
1: Jamieson BD, Ciric S, Fernandes P. Safety and Pharmacokinetics of Solithromycin in Subjects with Hepatic Impairment. Antimicrob Agents Chemother.
2: Vandevelde NM, Tulkens PM, Muccioli GG, Van Bambeke F. Modulation of the activity of moxifloxacin and solithromycin in an in vitro pharmacodynamic model of Streptococcus pneumoniae naive and induced biofilms. J Antimicrob Chemother. 2015 Feb 23. pii: dkv032.
3: Farrell DJ, Mendes RE, Jones RN. Antimicrobial Activity of Solithromycin against Serotyped Macrolide-Resistant Streptococcus pneumoniae Isolates Collected from U.S. Medical Centers in 2012. Antimicrob Agents Chemother. 2015 Apr;59(4):2432-4.
4: Keelan JA, Pugazhenthi K. Trans-placental passage and anti-inflammatory effects of solithromycin in the human placenta. Placenta. 2014 Dec;35(12):1043-8. doi: 10.1016/j.placenta.2014.09.009. Epub 2014 Sep 22.
5: Miura Y, Payne MS, Keelan JA, Noe A, Carter S, Watts R, Spiller OB, Jobe AH, Kallapur SG, Saito M, Stock SJ, Newnham JP, Kemp MW. Maternal intravenous treatment with either azithromycin or solithromycin clears Ureaplasma parvum from the amniotic fluid in an ovine model of intrauterine infection. Antimicrob Agents Chemother. 2014 Sep;
6: Jensen JS, Fernandes P, Unemo M. In vitro activity of the new fluoroketolide solithromycin (CEM-101) against macrolide-resistant and -susceptible Mycoplasma genitalium strains. Antimicrob Agents Chemother. 2014 Jun;58(6):3151-6. doi: 10.1128/AAC.02411-14. Epub 2014 Mar 17.
7: Piccinelli G, Fernandes P, Bonfanti C, Caccuri F, Caruso A, De Francesco MA. In vitro activity of solithromycin against erythromycin-resistant Streptococcus agalactiae. Antimicrob Agents Chemother. 2014;58(3):1693-8. doi: 10.1128/AAC.02210-13. Epub 2013 Dec 30. PubMed PMID: 24379197;
8: Mallegol J, Fernandes P, Melano RG, Guyard C. Antimicrobial activity of solithromycin against clinical isolates of Legionella pneumophila serogroup 1. Antimicrob Agents Chemother. 2014;58(2):909-15. doi:
9: Keelan JA, Kemp MW, Payne MS, Johnson D, Stock SJ, Saito M, Fernandes P, Newnham JP. Maternal administration of solithromycin, a new, potent, broad-spectrum fluoroketolide antibiotic, achieves fetal and intra-amniotic antimicrobial protection in a pregnant sheep model. Antimicrob Agents Chemother. 2014;58(1):447-54. doi: 10.1128/AAC.01743-13. Epub 2013 Nov 4.
10: Mallegol J, Fernandes P, Seah C, Guyard C, Melano RG. Determination of in vitro activity of solithromycin at different pHs and its intracellular activity tested against clinical isolates of Neisseria gonorrhoeae from a laboratory collection. Antimicrob Agents Chemother. 2013 Jun 24.
11: Kobayashi Y, Wada H, Rossios C, Takagi D, Charron C, Barnes PJ, Ito K. A novel macrolide/fluoroketolide, solithromycin (CEM-101), reverses corticosteroid insensitivity via phosphoinositide 3-kinase pathway inhibition. Br J Pharmacol. 2013 Jul;169(5):1024-34. doi: 10.1111/bph.12187.
NMR, HPLC 99.7%, LCMS, CAS:1476776-76-7, 1KG in stock
NMR, HPLC, LCMS, COA, Pls kindly check:
Product Name: N-tert-butyl-1H-indazole-7-carboxamide
CAS: 1476776-76-7
CAS: 1476776-76-7
Structure:
Purity 99.77%
Formula C12H15N3O
2017 China CPHI: E1M35
EOS Med Chem, Medchem is Big
執大象,天下往,往而無害,安平泰
労働時間: Beijing Time 4:00AM~11:00PM
郵箱: info@eosmedchem.com ; eosmedchem@gmail.com
辦公室: 0086-531-69905422-806(直通)
攜帶番號 & WhatsApp & Wechat: +8618653174435
住所: Diaozhen Chemical Industrial Park, Jinan City, China
Skype: willgutian
QQ: 2393923585
NMR, HPLC 99.2%, LCMS, tert-Butyl 3-amino-3-(hydroxymethyl)pyrrolidine-1-carboxylate, CAS: 889949-18-2, 30KG in stock
NMR, HPLC 99.2%, LCMS, tert-Butyl 3-amino-3-(hydroxymethyl)pyrrolidine-1-carboxylate, CAS: 889949-18-2, Pls kindly check:
Name: tert-Butyl 3-amino-3-(hydroxymethyl)pyrrolidine-1-carboxylate
CAS number 889949-18-2
MFCD number MFCD04115530
Formula C10H20N2O3
FW 216.3
Name: tert-Butyl 3-amino-3-(hydroxymethyl)pyrrolidine-1-carboxylate
CAS number 889949-18-2
MFCD number MFCD04115530
Formula C10H20N2O3
FW 216.3
2017 China CPHI: E1M35
EOS Med Chem, Medchem is Big
執大象,天下往,往而無害,安平泰
労働時間: Beijing Time 4:00AM~11:00PM
郵箱: info@eosmedchem.com ; eosmedchem@gmail.com
辦公室: 0086-531-69905422-806(直通)
攜帶番號 & WhatsApp & Wechat: +8618653174435
住所: Diaozhen Chemical Industrial Park, Jinan City, China
Skype: willgutian
QQ: 2393923585
NMR, HPLC99.2%, LCMS, 1-O-tert-butyl 3-O-methyl 3-aminopyrrolidine-1,3-dicarboxylate, CAS NO.:942190-47-8, 3KG in stock.
NMR, HPLC99.2%, LCMS, COA, Pls kindly check:
Name:1-O-tert-butyl 3-O-methyl 3-aminopyrrolidine-1,3-dicarboxylate
CAS NO.:942190-47-8
2017 China CPHI: E1M35
EOS Med Chem, Medchem is Big
執大象,天下往,往而無害,安平泰
労働時間: Beijing Time 4:00AM~11:00PM
郵箱: info@eosmedchem.com ; eosmedchem@gmail.com
辦公室: 0086-531-69905422-806(直通)
攜帶番號 & WhatsApp & Wechat: +8618653174435
住所: Diaozhen Chemical Industrial Park, Jinan City, China
Skype: willgutian
QQ: 2393923585
2017年10月24日星期二
NMR, HPLC 99.37%, LCMS, Maxacalcitol, CAS:103909-75-7, 6G in stock
NMR, HPLC 99%, LCMS, COA, Pls kindly check:
Name: Maxacalcitol
CAS NO.: 103909-75-7
Chemical Formula: C26H42O4
Exact Mass: 418.3083
Elemental Analysis: C, 74.60; H, 10.11; O, 15.29
Synonym: Maxacalcitol; Maxacalcitriol; 22-Oxacalcitriol;
IUPAC/Chemical Name: (1R,3S,Z)-5-(2-((1S,3aS,7aS,E)-1-((S)-1-(3-hydroxy-3-methylbutoxy)ethyl)-7a-methyloctahydro-4H-inden-4-ylidene)ethylidene)-4-methylenecyclohexane-1,3-diol
InChi Code: InChI=1S/C26H42O4/c1-17-20(15-21(27)16-24(17)28)9-8-19-7-6-12-26(5)22(10-11-23(19)26)18(2)30-14-13-25(3,4)29/h8-9,18,21-24,27-29H,1,6-7,10-16H2,2-5H3/b19-8+,20-9-/t18-,21+,22+,23-,24-,26+/m0/s1
TECHNICAL DATA
Appearance: Solid powder
Purity:99.37%
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and low temperature.
Solubility: Soluble in DMSO
Drug Formulation: This drug may be formulated in DMSO
REFERENCES
1: Karakawa M, Komine M, Kishimoto M, Maki N, Matsumoto A, Sugai J, Ohtsuki M. Effects of maxacalcitol ointment on skin lesions in patients with psoriasis receiving treatment with adalimumab. J Dermatol. 2016 Nov;43(11):1354-1357. doi: 10.1111/1346-8138.13515. Epub 2016 Jul 23.
2: Tada H, Shimizu T, Nagaoka I, Takada H. Vitamin D3 analog maxacalcitol (OCT) induces hCAP-18/LL-37 production in human oral epithelial cells. Biomed Res. 2016;37(3):199-205. doi: 10.2220/biomedres.37.199.
3: Nakamura K, Tohyama N, Yamasaki M, Ohta H, Morishita K, Takiguchi M. Hypercalcemia in a Dog with Chronic Ingestion of Maxacalcitol Ointment. J Am Anim Hosp Assoc. 2016 Jul-Aug;52(4):256-8. doi: 10.5326/JAAHA-MS-6286. Epub 2016 Jun 3.
4: Wróbel A, Rechberger T. The Influence of Maxacalcitol, Vitamin D3 Analog, on Detrusor Overactivity in Conscious Rats. Urology. 2016 Jul;93:224.e7-224.e15. doi: 10.1016/j.urology.2016.03.008. Epub 2016 Mar 23.
5: Fujii H, Nakai K, Yonekura Y, Kono K, Goto S, Hirata M, Shinohara M, Nishi S, Fukagawa M. The Vitamin D Receptor Activator Maxacalcitol Provides Cardioprotective Effects in Diabetes Mellitus. Cardiovasc Drugs Ther. 2015 Dec;29(6):499-507.
6: Umezawa Y, Nakagawa H, Tamaki K. Phase III clinical study of maxacalcitol ointment in patients with palmoplantar pustulosis: A randomized, double-blind, placebo-controlled trial. J Dermatol. 2016 Mar;43(3):288-93. doi: 10.1111/1346-8138.13064. Epub 2015 Aug 18.
7: Hoshina D, Tsujiwaki M, Furuya K. Successful treatment of subcorneal pustular dermatosis with maxacalcitol. Clin Exp Dermatol. 2016 Jan;41(1):102-3. doi: 10.1111/ced.12680. Epub 2015 May 19.
8: Akizawa T, Akiba T, Hirakata H, Kinugasa E, Tominaga Y, Fukagawa M, Yokoyama K, Zhang W, Linde PG, Suzuki M. Comparison of paricalcitol with maxacalcitol injection in Japanese hemodialysis patients with secondary hyperparathyroidism. Ther Apher Dial. 2015 Jun;19(3):225-34.
CAS NO.: 103909-75-7
Chemical Formula: C26H42O4
Exact Mass: 418.3083
Elemental Analysis: C, 74.60; H, 10.11; O, 15.29
Synonym: Maxacalcitol; Maxacalcitriol; 22-Oxacalcitriol;
IUPAC/Chemical Name: (1R,3S,Z)-5-(2-((1S,3aS,7aS,E)-1-((S)-1-(3-hydroxy-3-methylbutoxy)ethyl)-7a-methyloctahydro-4H-inden-4-ylidene)ethylidene)-4-methylenecyclohexane-1,3-diol
InChi Code: InChI=1S/C26H42O4/c1-17-20(15-21(27)16-24(17)28)9-8-19-7-6-12-26(5)22(10-11-23(19)26)18(2)30-14-13-25(3,4)29/h8-9,18,21-24,27-29H,1,6-7,10-16H2,2-5H3/b19-8+,20-9-/t18-,21+,22+,23-,24-,26+/m0/s1
TECHNICAL DATA
Appearance: Solid powder
Purity:99.37%
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and low temperature.
Solubility: Soluble in DMSO
Drug Formulation: This drug may be formulated in DMSO
2017 China CPHI: E1M35
EOS Med Chem, Medchem is Big
執大象,天下往,往而無害,安平泰
労働時間: Beijing Time 4:00AM~11:00PM
郵箱: info@eosmedchem.com ; eosmedchem@gmail.com
辦公室: 0086-531-69905422-806(直通)
攜帶番號 & WhatsApp & Wechat: +8618653174435
住所: Diaozhen Chemical Industrial Park, Jinan City, China
Skype: willgutian
QQ: 2393923585
REFERENCES
1: Karakawa M, Komine M, Kishimoto M, Maki N, Matsumoto A, Sugai J, Ohtsuki M. Effects of maxacalcitol ointment on skin lesions in patients with psoriasis receiving treatment with adalimumab. J Dermatol. 2016 Nov;43(11):1354-1357. doi: 10.1111/1346-8138.13515. Epub 2016 Jul 23.
2: Tada H, Shimizu T, Nagaoka I, Takada H. Vitamin D3 analog maxacalcitol (OCT) induces hCAP-18/LL-37 production in human oral epithelial cells. Biomed Res. 2016;37(3):199-205. doi: 10.2220/biomedres.37.199.
3: Nakamura K, Tohyama N, Yamasaki M, Ohta H, Morishita K, Takiguchi M. Hypercalcemia in a Dog with Chronic Ingestion of Maxacalcitol Ointment. J Am Anim Hosp Assoc. 2016 Jul-Aug;52(4):256-8. doi: 10.5326/JAAHA-MS-6286. Epub 2016 Jun 3.
4: Wróbel A, Rechberger T. The Influence of Maxacalcitol, Vitamin D3 Analog, on Detrusor Overactivity in Conscious Rats. Urology. 2016 Jul;93:224.e7-224.e15. doi: 10.1016/j.urology.2016.03.008. Epub 2016 Mar 23.
5: Fujii H, Nakai K, Yonekura Y, Kono K, Goto S, Hirata M, Shinohara M, Nishi S, Fukagawa M. The Vitamin D Receptor Activator Maxacalcitol Provides Cardioprotective Effects in Diabetes Mellitus. Cardiovasc Drugs Ther. 2015 Dec;29(6):499-507.
6: Umezawa Y, Nakagawa H, Tamaki K. Phase III clinical study of maxacalcitol ointment in patients with palmoplantar pustulosis: A randomized, double-blind, placebo-controlled trial. J Dermatol. 2016 Mar;43(3):288-93. doi: 10.1111/1346-8138.13064. Epub 2015 Aug 18.
7: Hoshina D, Tsujiwaki M, Furuya K. Successful treatment of subcorneal pustular dermatosis with maxacalcitol. Clin Exp Dermatol. 2016 Jan;41(1):102-3. doi: 10.1111/ced.12680. Epub 2015 May 19.
8: Akizawa T, Akiba T, Hirakata H, Kinugasa E, Tominaga Y, Fukagawa M, Yokoyama K, Zhang W, Linde PG, Suzuki M. Comparison of paricalcitol with maxacalcitol injection in Japanese hemodialysis patients with secondary hyperparathyroidism. Ther Apher Dial. 2015 Jun;19(3):225-34.
订阅:
评论 (Atom)



























